- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis in America Medical Cannabis Access for Pain Treatment
- Join Join
Pledges Not to Interfere with State Legal Cannabis Businesses
Contact: David Mangone | [email protected] | 202-857-4272 ext. 5
Washington, DC — During his Senate confirmation hearings today, the Attorney General nominee to replace Jeff Sessions, William Barr, indicated that he doesn't plan on using Department of Justice resources to prosecute cannabis businesses that are compliant with state law. Senators Cory Booker (D-NJ), Kamala Harris (D-CA) and Thom Tillis (R-NC) all questioned Barr about cannabis policy.
“My approach to this would be not to upset settled expectations and the reliant interests that have arisen as a result of the Cole memorandum,” Barr said, referring to the Justice Department document that previously laid out the department’s enforcement priorities. Barr added “I think it’s incumbent on the Congress to make a decision as to whether we’re going to have a federal system or whether it’s going to be essential federal law. This is breeding disrespect for the federal law.”
Barr went on to express his personal opposition to legalizing cannabis but indicated that it was up to Congress to rectify the conflict between state and federal policies. Sessions, Barr’s predecessor, was an outspoken opponent of cannabis who frequently questioned the value of cannabis as a medicine.
“William Barr’s commitment to former DOJ policies on medical cannabis is a refreshing and level-headed departure from the fear we lived in during the Sessions reign. While he is not a supporter of cannabis, he is joining patient advocates in our call to Congress to “get there in the right way” said Steph Sherer, President and Founder of Americans for Safe Access. “Creating a federal medical cannabis program would require things patient really care about like product safety, standardized, reliable products and a pathway to medical reimbursement or insurance coverage.”
Barr’s comments are consistent with a budget provision known as the Joyce-Blumenauer CJS Medical Marijuana Amendment that prevents the Department of Justice from spending money to interfere with state medical cannabis programs. Prior to the CJS Amendment’s passage, the Department of Justice spent nearly $600 million dollars interfering with medical cannabis programs and prosecuting patients.
For videos of Barr’s testimony, please click here.